President, Chief Executive Officer, & Director
Joining the board in 2020, Kim Murphy possesses a wealth of vaccine industry knowledge and experience that was vital to the company’s strategic acquisition of Noachis Terra, as well as the development of Oragenics’ other product candidates. Ms. Murphy served in a variety of vaccine-related leadership roles within GlaxoSmithKline plc (GSK). While with GSK, Ms. Murphy led the global influenza vaccine and pandemic preparedness businesses and was responsible for the strategic and prelaunch planning for multiple development-stage vaccines through commercialization. Earlier in her career, she worked in commercialization roles within Merck and Novartis Vaccines and Diagnostics Inc. Ms. Murphy currently serves as a director of Blue Water Vaccines, Inc. (NASDAQ: BWV) and as a director (chairperson) of Clarus Therapeutics Holdings Inc. (NASDAQ: CRXT). Ms. Murphy holds a B.A. in English from Old Dominion University and an MBA in Marketing from Saint Joseph’s University.
Chief Financial Officer & Interim Principal Executive Officer
Mr. Sullivan is serving as our Interim Principal Executive Officer. Mr. Sullivan previously served as our Interim Principal Executive Officer from October 30, 2014 until June 5, 2016. Mr. Sullivan is serving as our Chief Financial Officer, Secretary and Treasurer since February 6, 2012. Mr. Sullivan has held senior level financial positions for several publicly and privately held businesses including Utek Corporation, eANGLER, and HSN Direct International Limited. Most recently, he was the Group Financial Officer for the Investigative Services and Litigation Consulting Services segment of First Advantage Corporation a firm specializing in talent acquisition solutions where he streamlined the employee recruitment process. Mr. Sullivan is a Florida Certified Public Accountant. He graduated from the Florida State University with a Bachelor of Science in Accounting and a Master of Business Administration.
Martin (Marty) Handfield, PhD
Senior Vice President of Discovery Research
Dr. Martin (Marty) Handfield is Oragenics’ Senior Vice President of Discovery Research and has previously served as our Director of Research and Development. Prior to joining the company in 2009, Dr. Handfield held a position as Tenured Associate Professor at the Center for Molecular Microbiology and the Department of Oral Biology at the University of Florida College of Dentistry, where he co-invented IVIAT and co-founded IVI Gene Corporation and Epicure Corporation.
Dr. Handfield holds a B.S. in Biochemistry and an M.S. and PhD in Microbiology and Immunology from the Université Laval College of Medicine in Canada. He completed postdoctoral training at the University of Florida.